NewLink Genetics (NLNK) Reports Q2 Loss of $0.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
July 28, 2017 8:00 AM EDTAMES, Iowa, July 28, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ: NLNK) today reported consolidated financial results for the second quarter of 2017 and provided updates on its clinical development program for indoximod, NewLink Genetics small molecule targeting the IDO pathway with a distinct mechanism of action.
We continue to focus on indoximod, our... More
